AGP Executive Report
Last update: 3 hours agoCVS Restructuring: CVS Health beat third-quarter earnings estimates, raised its 2026 outlook and plans to split into two companies, separating its pharmacy business from insurance arm Aetna. Pharma Manufacturing: Merck will sell its contract drug-development and manufacturing business at five U.S. sites to Lonza, while AGC Biologics expanded a manufacturing deal worth more than €500 million to include its Copenhagen facility. Rare-Disease Access: England, Wales and Northern Ireland will extend NHS-funded access to Rhythm Pharmaceuticals’ IMCIVREE to adults with Bardet-Biedl syndrome. Health Data Privacy: Meta faces a class-action lawsuit alleging it tracked patients’ appointments, prescriptions and health conditions through medical apps. Fertility Research: Abu Dhabi’s ART Fertility Clinics and biotech firm dawn-bio plan a 2027 study of a new IVF embryo-culture system.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.